Dissecting monoclonal antibody mega-deals.
Monoclonal antibody (mAb) deals notable in size have made headlines recently. While deals with over US$ 1 bio in milestones were highly unusual in the past, even preclinical agreements, including some with very attractive co-promotion or profit-sharing clauses for the licensor, now reach this mark. This article presents an analysis of the structure of high-value mAb deals and the impact of increasingly sophisticated terms. Strategies of licensees and the impact of strategy on a deal's size and structure are also examined.
Villiger
Ralph
R
Avance, Basel GMbH, Basel, Switzerland. ralph.villiger@avance.ch
Bogdan
Boris
B
D000911:Antibodies, Monoclonal / Q000191:economics*; D035843:Biomedical Research / Q000191:economics / Q000331:legislation & jurisprudence / Q000458:organization & administration; D001709:Biotechnology / Q000191:economics / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D003299:Cooperative Behavior; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D006801:Humans
D000911:Antibodies, Monoclonal